Susquehanna Upgrades Sepracor (SEPR) to Neutral
More News related to SEPR
- Matrix Lighthouse Rating Changes 11/28
- Results of Studies of ALVESCO(R) for the Treatment of Asthma and OMNARIS(TM) in an HFA Nasal Aerosol Presented at American College of Allergy, Asthma & Immunology Annual Meeting
- David Moenning's Daily State of the Markets: 10/28
- Sepracor (SEPR) Reports Mixed Q3 Earnings; Guides FY08
- Sepracor Inc. Reports 9.6% Increase in Revenue for Third Quarter and Tightens Range for Full-Year 2008 Financial Guidance
More News related to Upgrades
- BMO Upgrades Spectrum Brands (SPC) to Market Perform
- Maxim Upgrades Palomar Medical (PMTI) to Buy
- RBC Capital Upgrades DSP Group (DSPG) to Sector Perform
- UBS Upgrades Morgans Hotel Group (MHGC) to Buy
- Janney Montgomery Scott Upgrades Wright Express Corp (WXS) to Buy.
Susquehanna upgrades Sepracor Inc. (Nasdaq: SEPR) from Negative to Neutral.
Susquehanna analyst says, "Today, we are taking an opportunity to update our financial forecasts to reflect current Rx trends. Our updated model reflects limited growth in Sepracor's major products (Xopenex HFA and Lunesta), but we are assuming a greater control in operating expenses for the remainder of 2008 and the out-years (2009-2012), as Lunesta television commercials are no longer omnipresent. Given the changes to our financial forecasts and more importantly the current valuation market of Sepracor, we are upgrading our rating to Neutral."
Sepracor Inc. is a research-based pharmaceutical company engaged in the discovery, development and commercialization of differentiated products that are prescribed by primary care physicians and certain specialists.
Related Categories
UpgradesStocks Mentioned
+0.49Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
